Andrew Cittadine - Mar 4, 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Quan Vu, Attorney-in-fact
Stock symbol
MNPR
Transactions as of
Mar 4, 2025
Transactions value $
$0
Form type
4
Date filed
3/7/2025, 09:09 PM
Previous filing
Jan 2, 2025
Next filing
Apr 2, 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +43.4K $0.00 43.4K Mar 4, 2025 Common Stock 43.4K $31.70 Direct F1
transaction MNPR Restricted Stock Units Award $0 +40.6K +366.45% $0.00 51.7K Mar 4, 2025 Common Stock 40.6K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options Vests 6/48ths on June 30, 2025, and 1/48th per month thereafter.
F2 RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.